Category: Corporate NewsBy adminJune 20, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to the EGX regarding UN Global Compact membershipNextNext post:EGX Disclosure on BOD and shareholding structureRelated PostsRameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024Rameda 4Q23 Earnings ReleaseMarch 20, 2024Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023Rameda Reports its 3Q23 ResultsNovember 14, 2023Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.November 6, 2023Rameda Reports its 2Q23 ResultsAugust 15, 2023
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023
Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.November 6, 2023
